In women, bisphosphonate use for ≥3 years vs. < 3 months was linked to increased atypical femur fracture risk.

In women, bisphosphonate use for ≥3 years vs. <3 months was linked to increased atypical femur fracture risk. Ann Intern Med. 2021 Jan 05;: Authors: Ott SM Abstract SOURCE CITATION: Black DM, Geiger EJ, Eastell R, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med. 2020;383:743-53. 32813950. PMID: 33395342 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33395342?dopt=Abstract

Source: Annals of Internal Medicine - January 5, 2021 Category: Internal Medicine Authors: Ott SM Tags: Ann Intern Med Source Type: research

More News: Internal Medicine | Women